Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorpromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 9/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 9/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorpromazine SCHEMBL8321 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL29367385 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL41771 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL8503036 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL27940552 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL23326209 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL29351728 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL5483904 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL29714121 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL27869706 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2D6HTR1ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-3411059-B1 | METHOD TO ENHANCE THE EFFICIENCY OF SYSTEMIC AAV GENE DELIVERY TO THE CENTRAL NERVOUS SYSTEM | UNIV MASSACHUSETTS (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4203942-B1 | IBRUTINIB FOR USE IN TREATING COCAINE USE DISORDER AND RELATED CONDITIONS | UNIV EMORY (US) | 2026-04-15 | — | — | EP | claimed |
| EP-3194027-B1 | COMPOSITIONS FOR USE IN TREATING PSYCHOTIC DISORDERS | SOUND PHARMACEUTICALS INCORPORATED (US) | 2026-02-11 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4396883-B1 | REDOX FLOW BATTERY | GREEN ENERGY STORAGE S R L (IT) | 2025-12-24 | — | — | EP | claimed |
| EP-3334725-B1 | BROMODOMAIN AND EXTRA TERMINAL (BET) INHIBITOR AND A PROTEIN PHOSPHATASE 2A (PP2A) ACTIVATOR FOR TREATING BET INHIBITOR RESISTANT CANCER | DANA FARBER CANCER INST INC (US) | 2025-04-23 | — | — | EP | claimed |
| EP-3899543-B1 | FLOW CELLS AND SEQUENCING KITS | ILLUMINA INC (US) | 2025-03-19 | — | — | EP | claimed |
| EP-3180349-B1 | LYMPH DIRECTING PRODRUGS AND THERAPEUTIC USES THEREOF | UNIV MONASH (AU) | 2025-03-12 | — | — | EP | claimed |
| EP-3830103-B1 | FLUORINATED BILE ACID DERIVATIVES | NZP UK LTD (GB) | 2023-11-08 | — | — | EP | claimed |
| EP-3125893-B1 | DEUTERATED HETEROCYCLE FUSED GAMMA-CARBOLINES AS ANTAGONISTS OF 5-HT2A RECEPTORS | INTRA CELLULAR THERAPIES INC (US) | 2023-09-20 | — | — | EP | claimed |
| CN-116684442-A | Internet of vehicles trusted data sharing method and system based on deep reinforcement learning | 杭州师范大学 | 2023-09-01 | — | — | CN | claimed |
| EP-3697386-B1 | LIQUID COMPOSITIONS FOR PERORAL USE COMPRISING PHOSPHATIDYLGLYCEROL DERIVATIVES AND THIXOTROPIC EXCIPIENTS FOR TREATING CARDIAC CHANNELOPATHIES CAUSED BY PHARMACOLOGICAL AGENTS | SIGNPATH PHARMA INC (US) | 2023-07-26 | — | — | EP | claimed |
| EP-3151837-B1 | PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES | SIGNPATH PHARMA INC (US) | 2023-03-15 | — | — | EP | claimed |
| EP-3437659-B1 | COMBINATION OF A FXR AGONIST AND AN ANGIOTENSIN II RECEPTOR BLOCKER | INTERCEPT PHARMACEUTICALS INC (US) | 2023-03-01 | — | — | EP | claimed |
| CN-115577840-A | Operation management method for electric buses in alpine cities based on double-battery configuration | 吉林大学 | 2023-01-06 | — | — | CN | claimed |
| EP-3891505-B1 | A METHOD FOR MEASURING A CONCENTRATION OF A BIOMARKER/ANALYTE IN BLOOD FROM MAMMALS | REDHOTDIAGNOSTICS AB (SE) | 2022-11-30 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| WO-2022098106-A1 | COMPOSITION FOR PREVENTING OR TREATING NEUROINFLAMMATORY DISEASES, COMPRISING CHLORPROMAZINE | 주식회사 오에이티씨 | 2022-05-12 | — | — | WO | claimed |